Delayed recovery after
gastrectomy may preclude the administration of adjuvant
therapy in a significant percentage of patients who undergo elective
gastrectomy as the initial
therapy for
gastric cancer. Clinicopathologic and treatment variables of 155 patients undergoing potentially curative
gastrectomy for stages Ib-IIIc gastric
adenocarcinoma from 2001 to 2014 were analyzed, and rates of receipt of
chemotherapy and
radiotherapy in patients treated with either a surgery-first approach (SURG) or
neoadjuvant therapy followed by surgery followed by postoperative
therapy (PERIOP) were compared. SURG patients (n = 93) were older and more likely to have distal
tumors and to undergo distal
gastrectomy and D1
lymphadenectomy than PERIOP patients (n = 62). The distribution of ASA scores was similar between groups. SURG patients were less likely than PERIOP patients to complete at least one cycle of
chemotherapy (56 vs 100%, P = 0.001) and all recommended
chemotherapy and
radiation therapy (44 vs 66%, P = 0.013). These findings were consistent for SURG patients treated during different time periods throughout the study and for patients of poorer performance status. A significantly higher percentage of
gastric cancer patients treated with perioperative
chemotherapy receive some or all of the recommended components of multimodality
therapy than patients treated with a surgery-first approach.